PYC-003

PYC has developed a new drug candidate for the >5 million people worldwide[1] with Polycystic Kidney Disease (PKD) This drug candidate has demonstrated efficacy in human models derived from the kidneys of patients with end-stage renal failure due to PKD [2] PKD is a life-changing disease affecting 1 in every 1,000 people[3] Half of the patient population with PKD will require a kidney transplant by the age of 60 due to the absence of impactful treatment options in this disease[4] PKD represents an addressable market of >US$10 billion p.a. and is an area of major commercial interest for the drug development industry[5] Pre-clinical models suggest that addressing the underlying cause of PKD (the way that PYC's drug candidate works) could arrest the course of the disease in humans, enabling damaged kidneys to regenerate and restore function[6] PYC plans to accelerate this drug candidate into human trials in ~12 months – pursuing a potential high-velocity path through clinical trials to market[7] Investor Webinar Friday 17 November PYC will host an investor call at 9am AWST/12pm AEDST on Friday 17 November to discuss these results – investors can register for the call here: PERTH, Australia and SAN FRANCISCO, Nov. 13, 2023 /PRNewswire/ -- PYC Therapeutics today announces the results of a study conducted in human 3-dimensional models derived from patients with end-stage renal failure due to Autosomal Dominant Polycystic Kidney Disease (PKD). The results demonstrate that an investigational drug candidate designed by PYC (known as PYC-003) to address this disease at its root cause is effective. These 3D patient-derived cyst models represent the 'gold-standard' pre-clinical assay for evaluating drug candidates in this indication[8]. Continue Reading Figure 1 Figure 2 Figure 3 Figure 4